Sanofi signed a deal worth up to $4.2 billion to get its hands on a trio of diabetes treatments from South Korean drugmaker Hanmi Pharmaceutical, filling out its pipeline as it contends with rivals Novo Nordisk and Eli Lilly.
Novo Nordisk CEO Lars Rebien Sørensen speaks of stingy payers and global competition in the world diabetes market, while Sanofi told investors its diabetes drug sales will fall through 2018. But none of this has deterred insulin specialist Novo,...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Novo Nordisk A/S (NVO):